Current and new antimicrobial agents

American Heart Journal

Volumn 147, Issue 4, 2004, Pages 587-592

  Eliopoulos, George M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; GLYCOPEPTIDE; LINEZOLID; MACROLIDE; NAFCILLIN; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; BONE MARROW SUPPRESSION; CARDIOVASCULAR SURGERY; CLINICAL TRIAL; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HOSPITAL INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; MYOPATHY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROSTHESIS INFECTION; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 3142581351     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.06.006     Document Type: Article

References (52)

1. Cabell C.H., Abrutyn E. Progress toward a global understanding of infective endocarditis. Early lessons from the International Collaboration on Endocarditis investigation. Infect Dis Clin North Am. 16:2002;255-272
2. Miró J.M., del Rio A., Mestres C.A. Infective endocarditis in intravenous drug abusers and HIV-1 infected patients. Infect Dis Clin North Am. 16:2002;273-295
3. Camus C., Leport C., Raffi F., et al. Sustained bacteremia in 26 patients with permanent endocardial pacemaker Assessment of wire removal. Clin Infect Dis. 17:1993;46-55
4. Kearney R.A., Eisen H.J., Wolf J.E. Nonvalvular infections of the cardiovascular system. Ann Intern Med. 121:1994;219-230
5. Malanoski G.J., Samore M.H., Pefanis A., et al. Staphylococcus aureus catheter-associated bacteremia. Arch Intern Med. 155:1995;1161-1166
6. Petti C.A., Fowler V.G. Staphylococcus aureus bacteremia and endocarditis. Infect Dis Clin North Am. 16:2002;413-435
7. Gordon S.M., Schmitt S.K., Jacobs M., et al. Nosocomial bloodstream infections in patients with implantable left ventricular assist devices. Ann Thorac Surg. 72:2001;725-730
8. Douglas J.L., Cobbs C.G. Prosthetic valve endocarditis. Kaye D. Infective endocarditis. 2nd ed:1992;375-396 Raven Press, New York
9. Karchmer A.W., Longworth D.L. Infections of intracardiac devices. Infect Dis Clin North Am. 16:2002;477-505
10. Diekema D.J., Pfaller M.A., Schmitz F.J., et al. Survey of infections due to Staphylococcus species Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 32:(2 Suppl):2001;S114-132
11. Fluit A.C., Wielders C.L., Verhoef J., et al. Epidemiology and susceptibility of 3051 Staphylococcus aureus isolates from 25 university hospitals participating in the European SENTRY study. J Clin Microbiol. 39:2001;3727-3732
12. NCCLS. Performance standards for antimicrobial susceptibility testing; twelfth informational supplement. 2002;NCCLS, Wayne (Pa). p. 96
13. Quintiliani R., Sahm D.F., Courvalin P. Mechanisms of resistance to antimicrobial agents. Murray P.F., Baron E.J., Pfaller M.A., et al. Manual of clinical microbiology. 7th edition:1999;1505-1525 American Society for Microbiology, Washington, DC
14. Tenover F.C., Biddle J.W., Lancaster M.V. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis. 7:2001;327-332
15. Andrade-Baiocchi S., Tognim M.C.B., Baiocchi O.C.G., et al. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus Case report and strain characterization. Diagn Microbiol Infect Dis. 45:2003;149-152
16. Fridkin S.K., Hageman J., McDougal L.K., et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis. 36:2003;429-439
17. Sieradzki K., Roberts R.B., Haber S.W., et al. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med. 340:1999;517-523
18. Finan J.E., Archer G.L., Climo M.W. Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 45:2001;3070-3075
19. CDC. Staphylococcus aureus resistant to vancomycin - United States, 2002. Mor Mortal Wkly Rep CDC Surveill Summ. 51:2002;565-567
20. CDC. Vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. Morb Mortal Wkly Rep. 51:2002;902
21. Watanakunakorn C., Glotzbecker C. Enhancement of the effects of anti-staphylococcal antibiotics by aminoglycosides. Antimicrob Agents Chemother. 6:1974;802-806
22. Korzeniowski O., Sande M.A. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts A prospective study. Ann Intern Med. 97:1982;496-503
23. Gilbert D.N., Moellering R.C. Jr, Sande M.A. editors. 2002;Antimicrobial Therapy, Inc, The Sanford guide to antimicrobial therapy. Hyde Park, Vt
24. Levine D.P., Fromm B.S., Reddy B.R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 115:1991;674-680
25. Fuchs P.C., Barry A.L., Brown S.D. In vitro bactericidal therapy of daptomycin against staphylococci. J Antimicrob Chemother. 49:2002;467-470
26. Turnidge J., Chang F.-Y., Fowler V.G., et al. Staphylococcus aureus. Yu V.L., Weber R., Raoult D. Antimicrobial therapy and vaccines. 2nd ed. Volume I: microbes:2002;631-658 Apple Tree Productions, New York
27. Batts D.H., Lavin B.S., Eliopoulos G.M. Quinupristin/dalfopristin and linezolid Spectrum of activity and potential roles in therapy - a status report. Curr Clin Top Infect Dis. 21:2001;227-251
28. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003;36:473-81
29. Ballow C.H., Jones R.N., Biedenbach D.J., et al. A multicenter evaluation of linezolid antimicrobial activity in North America. Diag Microbiol Infect Dis. 43:2002;75-83
30. Fuchs P.C., Barry A.L., Brown S.D. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus Clindamycin susceptibility as a surrogate indicator. Antimicrob Agents Chemother. 44:2000;2880-2882
31. Quinupristin-dalfopristin (Synercid) package literature. Bridgewater (NJ): Aventis Pharmaceutical Products; 2000
32. Olsen K.M., Rebuck J.A., Rupp M.E. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis. 32:2001;e83-86
33. Tsiodras S., Gold H.S., Sakoulas G., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 358:2001;207-208
34. Wilson P., Andrews J.A., Charlesworth R., et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 51:2003;186-188
35. Gonzales R.D., Schreckenberger P.C., Graham M.B., et al. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet. 357:2001;1179
36. Linezolid (Zyvox) package literature. Kalamazoo (Mich): Pharmacia & Upjohn Corporation; 2001
37. Stevens D.L., Herr D., Lampiris H., et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 34:2002;1481-1490
38. Moise P.A., Forrest A., Birmingham M.C., et al. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother. 50:2002;1017-1026
39. Ruiz M.E., Guerrero I.C., Tuazon C.U. Endocarditis caused by methicillin-resistant Staphylococcus aureus Treatment failure with linezolid. Clin Infect Dis. 35:2002;1018-1020
40. Halpern M. Linezolid-induced pancytopenia. Clin Infect Dis. 35:2002;347-348
41. Gerson S.L., Kaplan S.L., Bruss J.B., et al. Hematologic effects of linezolid Summary of clinical experience. Antimicrob Agents Chemother. 46:2002;2723-2726
42. Orrick J.J., Johns T., Janelle J., et al. Thrombocytopenia secondary to linezolid administration What is the risk? Clin Infect Dis. 35:2002;348-349
43. Attassi K., Hershberger E., Alam R., et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 34:2002;695-698
44. Wigen C.L., Goetz M.B. Serotonin syndrome and linezolid. Clin Infect Dis. 34:2002;1651-1652
45. Tally F.P., DeBruin M.F. Development of daptomycin for gram-positive infections. J Antimicrob Chemother. 46:2000;523-526
46. Petersen P.J., Bradford P.A., Weiss W.J., et al. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother. 46:2002;2595-2601
47. Barry A.L., Fuchs P.C., Brown S.D. In vitro activities of daptomycin against 2789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother. 45:2001;1919-1922
48. Zeckel M.L., Preston D.A., Allen B.S. In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study. Antimicrob Agents Chemother. 44:2000;1370-1374
49. Schwalbe R.S., McIntosh A.C., Qaiyumi S., et al. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother. 40:1996;2416-2419
50. Barrett J.F. Oritavancin Eli Lilly & Co. Curr Opin Invest Drugs. 2:2001;1039-1044
51. Candiani G., Abbondi M., Borgonovi M., et al. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother. 44:1999;179-192
52. Selzer E., Dorr M.B., Goldstein B.P., et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 37:2003;1298-1303